Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Gene therapy, recently frequently investigated, is an alternative treatment method that
introduces therapeutic genes into a cancer cell or tissue to cause cell death or slow down …

A molecular classification of diseases that accurately reflects clinical behaviour lays the
foundation of precision medicine. The development of in silico classifiers coupled with …

Peripheral blood inflammatory indices, like the neutrophil-to-lymphocyte ratio (NLR), may
reflect the host's pro-inflammatory status and systemic immune response to cancer-related …

While new targeted therapies have considerably changed the treatment and prognosis of
non-small cell lung cancer (NSCLC), they are frequently unsuccessful due to primary or …

Introduction Lung cancer remains the deadliest cancer in the world, and lung cancer survival
is heavily dependent on tumor stage at the time of detection. Low-dose computed …

Introduction PD-(L) 1 inhibitors (IO) have improved the prognosis of non-small-cell lung
cancer (NSCLC), but more reliable predictors of efficacy and immune-related adverse …

Background It has been reported that smoking history as a predictor of immunotherapy
efficacy in patients with advanced lung cancer, however, the underlying mechanisms of this …

Cancer is a complex and heterogeneous disease that poses a significant threat to global
health. Early diagnosis and treatment are critical for improving patient outcomes, and the …

Immune checkpoints inhibitors (ICIs) have markedly improved the therapeutic management
of advanced NSCLC and, more recently, they have demonstrated efficacy also in the early …